CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CareDx reports solid Q4 earnings, eyes profitable growth in 2023

CareDx delivered strong financial results, focusing on profitable growth and strategic initiatives to drive revenue and market leadership.
While facing challenges such as fluctuating transplant volumes and market risks, the company is actively pursuing opportunities for expansion and innovation.
Overall, CareDx's performance, strengths, and proactive approach to challenges and opportunities position it for continued success and growth in the coming year.

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., June  18, 2020  (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 585,937 shares of common stock at the public offering price of $32.00 per share, less underwriting discounts and commissions, for additional net proceeds to CareDx of approximately $17.6 million.  The option was granted in connection with the public offering of 3,906,250 shares of common stock at a public offering price of $32.00 per share, which closed on June 15, 2020.

CareDx Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

CareDx congratulates C-Path’s Transplant Therapeutics Consortium on utilizing iBox to streamline the development of novel transplant drugs CareDx congratulates C-Path’s Transplant Therapeutics Consortium on utilizing iBox to streamline the development of novel transplant drugs

FDA Accepts Letter of Intent for iBox Scoring System as a Surrogate Endpoint in Pharmaceutical Clinical Trials

SOUTH SAN FRANCISCO, Calif., June  08, 2020  (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a change to its 2020 Annual Meeting of Stockholders.  Due to conditions associated with the impact of the Coronavirus pandemic (COVID-19), including restrictions on in-person gatherings, and in order to support the health and well-being of our stockholders and other meeting participants, CareDx’s 2020 Annual Meeting of Stockholders will be held in a virtual meeting format only.

CareDx Announces 2020 Annual Meeting of Stockholders to be Held as a Virtual Meeting

CE Mark approval enables global availability of innovative Hybrid-Capture Technology HLA testing for transplant patients CE Mark approval enables global availability of innovative Hybrid-Capture Technology HLA testing for transplant patients

CareDx's AlloSeq Tx 17 Awarded CE Mark Approval

UroMap Gene Expression Test Will Add to CareDx’s Best In Class Transplant Surveillance Comprehensive Solutions UroMap Gene Expression Test Will Add to CareDx’s Best In Class Transplant Surveillance Comprehensive Solutions

CareDx Collaborates with Weill Cornell Medicine to Lead the Development and Commercialization of UroMap

CareDx, Inc (CDNA) CEO Peter Maag on Q1 2020 Results - Earnings Call Transcript

CareDx (CDNA) delivered earnings and revenue surprises of -100.00% and 0.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) Reports Break-Even Earnings for Q1

Leaders in HLA and transplant laboratory solutions will present at CareDx virtual symposiums originally planned for EFI Leaders in HLA and transplant laboratory solutions will present at CareDx virtual symposiums originally planned for EFI

CareDx Engages European Lab Community in Virtual Meetings

CareDx: A Robust Transplant Diagnostics Pick For 2020

CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: CareDx (CDNA) Q1 Earnings Expected to Decline

One outcome from the coronavirus pandemic could be the adoption of CareDx Inc (NASDAQ: CDNA)’s management platform for organ transplant patients.

CareDx CEO Says Pandemic Proves Value Of Remote Transplant Monitoring System

CareDx Announces Collaborations to Develop Cellular Therapy Diagnostics CareDx Announces Collaborations to Develop Cellular Therapy Diagnostics

CareDx Introduces AlloCell: Cell Therapy Surveillance

CareDx Collaborates with ExamOne, a Quest Diagnostics Company, to Expand Mobile Phlebotomy Coverage Across the United States for Transplant Patients who are High Risk for COVID-19 CareDx Collaborates with ExamOne, a Quest Diagnostics Company, to Expand Mobile Phlebotomy Coverage Across the United States for Transplant Patients who are High Risk for COVID-19

CareDx Mobilizes 10,000 Phlebotomists for Home Blood Draws of Transplant Patients with RemoTraC

SOUTH SAN FRANCISCO, Calif., April  08, 2020  (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high value healthcare solutions for transplant patients and caregivers, today announced preliminary unaudited revenue for the three months ended March 31, 2020 and withdrew its previously issued full year 2020 revenue guidance.

CareDx Reports Preliminary First Quarter 2020 Revenue and Provides Business Update in Response to COVID-19 Pandemic

CareDx works with International Consortium of Transplant Leaders on a Global Registry of Transplant Patients Diagnosed with COVID-19 CareDx works with International Consortium of Transplant Leaders on a Global Registry of Transplant Patients Diagnosed with COVID-19

CareDx Supports Launch of International COVID-19 Transplant Registry (C19TxR)

CareDx Congratulates Johns Hopkins on Successful Follow-Up Using AlloSure of First Retransplant Patient After Immunotherapy CareDx Congratulates Johns Hopkins on Successful Follow-Up Using AlloSure of First Retransplant Patient After Immunotherapy

REPEAT - New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy

New AJT Publication: AlloSure Monitors First Patient Retransplanted After Anti-PD-L1 Cancer Therapy

Investors need to pay close attention to CareDx (CDNA) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in CareDx (CDNA) Stock?

CareDx brings remote solutions to the immunosuppressed transplant community to address COVID-19 concerns CareDx brings remote solutions to the immunosuppressed transplant community to address COVID-19 concerns

CareDx Launches RemoTraC: Home-Based Monitoring of Transplant Patients

CareDx CMO to Chair Upcoming NKF San Francisco Kidney Walk CareDx CMO to Chair Upcoming NKF San Francisco Kidney Walk

CareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney Transplant Community

CareDx Inc. (CDNA) CEO Peter Maag on Q4 2019 Results - Earnings Call Transcript

CareDx (CDNA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Accuray

Owens & Minor

Smith Micro Software

Synaptics

Vista Outdoor

President Trump's tenure has seen Wall Street perform exceptionally well so far. In fact, Trump often cites Wall Street's bull run as a reflection of his good governance.

Trump Mulling Tax Cuts to Incentivize Stock Buying? 6 Picks

IP decision follows recent success in false advertising case IP decision follows recent success in false advertising case

CareDx’s Patent Rights Upheld By Delaware Court

CareDx (CDNA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for CareDx Stock (CDNA)